

# Martin W Häußler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4717200/publications.pdf>

Version: 2024-02-01

121  
papers

2,826  
citations

159585

30  
h-index

214800

47  
g-index

124  
all docs

124  
docs citations

124  
times ranked

3532  
citing authors

#	ARTICLE	IF	CITATIONS
1	[18F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact. <i>European Radiology</i> , 2022, 32, 508-516.	4.5	41
2	Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study. <i>European Radiology</i> , 2022, 32, 1823-1832.	4.5	17
3	Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and 68Ga-PSMA-PET/MRI – What is the value of quantitative data from multiparametric MRI alone or in conjunction with clinical information?. <i>European Journal of Radiology</i> , 2022, 146, 110044.	2.6	9
4	SUVmax for predicting regional control in oropharyngeal cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 3167-3177.	1.6	3
5	[18F]-sodium fluoride PET/MR for painful lumbar facet joint degeneration – a randomized controlled clinical trial. <i>Spine Journal</i> , 2022, 22, 769-775.	1.3	6
6	Expanding the clinicopathological spectrum of <i>TGFBR3</i> rearranged salivary gland neoplasms with myoepithelial differentiation including evidence of high-grade transformation. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 94-104.	2.8	11
7	Histopathological Features of Parathyroid Adenoma and 18F-Choline Uptake in PET/MR of Primary Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2022, 47, 101-107.	1.3	9
8	Frequency and intensity of [ <sup>18</sup> F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET. <i>BJR Open</i> , 2022, 4, .	0.6	1
9	An essential practice summary of the new EANM guidelines for parathyroid imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.7	5
10	BSREM for Brain Metastasis Detection with 18F-FDG-PET/CT in Lung Cancer Patients. <i>Journal of Digital Imaging</i> , 2022, 35, 581-593.	2.9	5
11	FDG-PET/CT for oral focus assessment in head and neck cancer patients. <i>Clinical Oral Investigations</i> , 2022, 26, 4407-4418.	3.0	1
12	Value of FDG-PET/MR in Oral Focus Assessment in Head and Neck Cancer Patients – A Feasibility Study. <i>Frontiers in Medicine</i> , 2022, 9, 809323.	2.6	1
13	Reproducibility of Standardized Uptake Values Including Volume Metrics Between TOF-PET-MR and TOF-PET-CT. <i>Frontiers in Medicine</i> , 2022, 9, 796085.	2.6	1
14	NEMA NU 2 – 2018 performance evaluation of a new generation 30-cm axial field-of-view Discovery MI PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3023-3032.	6.4	10
15	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. <i>Frontiers in Oncology</i> , 2022, 12, 830627.	2.8	2
16	Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series. <i>Head and Neck Pathology</i> , 2022, , .	2.6	1
17	Impact of Bayesian penalized likelihood reconstruction on quantitative and qualitative aspects for pulmonary nodule detection in digital 2-[18F]FDG-PET/CT. <i>Scientific Reports</i> , 2022, 12, 8308.	3.3	2
18	PET/MR in Head and Neck Cancer – An Update. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 26-38.	4.6	30

#	ARTICLE	IF	CITATIONS
19	Hybrid positron emission tomography imaging for initial staging of sinonasal tumors: Total lesion glycolysis as prognosticator of treatment response. <i>Head and Neck</i> , 2021, 43, 238-246.	2.0	6
20	Treatment Monitoring of Immunotherapy and Targeted Therapy Using <sup>18</sup> F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021, 62, 464-470.	5.0	25
21	Impact of PET data driven respiratory motion correction and BSREM reconstruction of <sup>68</sup> Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS). <i>Scientific Reports</i> , 2021, 11, 2273.	3.3	15
22	Whole-body parametric [ <sup>18</sup> F]-FDG PET/CT improves interpretation of a distant lesion as venous embolus in a lung cancer patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2047-2048.	6.4	3
23	CT perfusion in peripheral arterial disease—hemodynamic differences before and after revascularisation. <i>European Radiology</i> , 2021, 31, 5507-5513.	4.5	11
24	PET/CT in therapy control of infective native aortic aneurysms. <i>Scientific Reports</i> , 2021, 11, 5065.	3.3	9
25	<sup>18</sup> F-FDG PET/CT/MRI in head and neck squamous cell carcinoma: Impact on pretherapeutic N classification, detection of distant metastases, and second primary tumors. <i>Head and Neck</i> , 2021, 43, 2058-2068.	2.0	6
26	Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [ <sup>18</sup> F]FDG PET/CT. <i>European Radiology</i> , 2021, 31, 8011-8020.	4.5	12
27	FDG-PET/CT: novel method for viability assessment of livers perfused ex vivo. <i>Nuclear Medicine Communications</i> , 2021, 42, 826-832.	1.1	2
28	A pilot study on lung cancer detection based on regional metabolic activity distribution in digital low-dose <sup>18</sup> F-FDG PET. <i>British Journal of Radiology</i> , 2021, 94, 20200244.	2.2	1
29	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. <i>Molecules</i> , 2021, 26, 2201.	3.8	23
30	The EANM practice guidelines for parathyroid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2801-2822.	6.4	116
31	Who's Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma. <i>Cancers</i> , 2021, 13, 2725.	3.7	7
32	Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma – Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes. <i>Frontiers in Oncology</i> , 2021, 11, 664304.	2.8	14
33	The role of <sup>99m</sup> Tc-antigranulocyte SPECT/CT in community-acquired diabetic foot osteomyelitis: A clinical experience. <i>Current Diabetes Reviews</i> , 2021, 17, .	1.3	0
34	COVID-19 and Aspiration Pneumonia: Similar Pulmonary Findings with Different Diagnoses—a Pitfall in [ <sup>18</sup> F]FDG PET/CT. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 2322-2325.	0.6	0
35	Impact of unknown incidental findings in PET/CT examinations of patients with proven or suspected vascular graft or endograft infections. <i>Scientific Reports</i> , 2021, 11, 13747.	3.3	6
36	PET/CT helps to determine treatment duration in patients with resected as well as inoperable alveolar echinococcosis. <i>Parasitology International</i> , 2021, 83, 102356.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. <i>EJNMMI Research</i> , 2021, 11, 79.	2.5	11
38	<scp>Whole-body</scp> hybrid positron emission tomography imaging yields clinically relevant information in the staging and restaging of sinonasal tumors. <i>Head and Neck</i> , 2021, 43, 3572-3585.	2.0	6
39	Clinical evaluation of data-driven respiratory gating for PET/CT in an oncological cohort of 149 patients: impact on image quality and patient management. <i>British Journal of Radiology</i> , 2021, 94, 20201350.	2.2	9
40	Impact of PET/CT among patients with suspected mycotic aortic aneurysms. <i>PLoS ONE</i> , 2021, 16, e0258702.	2.5	5
41	True absopal effect in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 194.	2.7	8
42	<sup>68</sup> Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 147-159.	6.4	43
43	Evaluation of <sup>18</sup> F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 163-170.	2.0	7
44	The potential of machine learning to predict postoperative pancreatic fistula based on preoperative, non-contrast-enhanced CT: A proof-of-principle study. <i>Surgery</i> , 2020, 167, 448-454.	1.9	43
45	Tumor cell viability in salvage neck dissections: Poor prognosis predicted by high postradiation nodal SUV max, p16 negativity, and low nodal shrinkage. <i>Head and Neck</i> , 2020, 42, 660-669.	2.0	4
46	Artificial intelligence for detecting small FDG-positive lung nodules in digital PET/CT: impact of image reconstructions on diagnostic performance. <i>European Radiology</i> , 2020, 30, 2031-2040.	4.5	39
47	<sup>18</sup> F-NaF-PET/CT in patients with primary hyperparathyroidism and brown tumors. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 299-309.	2.7	7
48	<sup>18</sup> F-FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 113-117.	1.3	17
49	32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii5-ii6.	0.7	1
50	Predictive value of summax changes between two sequential post-therapeutic FDG-pet in head and neck squamous cell carcinomas. <i>Scientific Reports</i> , 2020, 10, 16689.	3.3	4
51	Histometabolic Tumor Imaging of Hypoxia in Oral Cancer: Clinicopathological Correlation for Prediction of an Aggressive Phenotype. <i>Frontiers in Oncology</i> , 2020, 10, 1670.	2.8	11
52	Prognostic value of O-(2-[ <sup>18</sup> F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. <i>Acta Oncologica</i> , 2020, 59, 1357-1364.	1.8	0
53	Nutrient Challenge Testing Is Not Equivalent to Scintigraphy~Lactulose Hydrogen Breath Testing in Diagnosing Small Intestinal Bacterial Overgrowth. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 514-520.	2.4	0
54	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. <i>Diagnostics</i> , 2020, 10, 1083.	2.6	23

#	ARTICLE	IF	CITATIONS
55	The impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases: A simulation study combining multi-center data and ADNI-data. PLoS ONE, 2020, 15, e0233886.	2.5	6
56	Value of SUVmax for the Prediction of Bone Invasion in Oral Squamous Cell Carcinoma. Biology, 2020, 9, 23.	2.8	13
57	Diagnostic accuracy of computed tomography and magnetic resonance imaging compared to surgical exploration for anterior skull base and medial orbital wall infiltration in advanced sinonasal tumors. Head and Neck, 2020, 42, 2002-2012.	2.0	10
58	Primary cardiac lymphoma. European Heart Journal Cardiovascular Imaging, 2020, 21, 816-816.	1.2	0
59	Reference values of physiological 18F-FET uptake: Implications for brain tumor discrimination. PLoS ONE, 2020, 15, e0230618.	2.5	7
60	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. Clinical Cancer Research, 2020, 26, 4414-4425.	7.0	70
61	Diagnostic Accuracy of PET/CT and Contrast Enhanced CT in Patients With Suspected Infected Aortic Aneurysms. European Journal of Vascular and Endovascular Surgery, 2020, 59, 972-981.	1.5	26
62	Title is missing!. , 2020, 15, e0233886.		0
63	Title is missing!. , 2020, 15, e0233886.		0
64	Title is missing!. , 2020, 15, e0233886.		0
65	Title is missing!. , 2020, 15, e0233886.		0
66	CT-perfusion in peripheral arterial disease: Correlation with angiographic and hemodynamic parameters. PLoS ONE, 2019, 14, e0223066.	2.5	14
67	Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. Cancers, 2019, 11, 1329.	3.7	9
68	Impact of different image reconstructions on PET quantification in non-small cell lung cancer: a comparison of adenocarcinoma and squamous cell carcinoma. British Journal of Radiology, 2019, 92, 20180792.	2.2	20
69	Interchangeability of radiomic features between [18F]FDG PET/CT and [18F]FDG PET/MR. Medical Physics, 2019, 46, 1677-1685.	3.0	22
70	Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suvmax) In Laryngeal and Hypopharyngeal Cancer. Scientific Reports, 2019, 9, 8972.	3.3	21
71	Current concepts in advanced sinonasal mucosal melanoma: a single institution experience. European Archives of Oto-Rhino-Laryngology, 2019, 276, 2259-2265.	1.6	13
72	Use of MRI and FDG-PET/CT to predict fixation of advanced hypopharyngeal squamous cell carcinoma to prevertebral space. Head and Neck, 2019, 41, 503-510.	2.0	8

#	ARTICLE	IF	CITATIONS
73	Comparing diagnostic accuracy of 18F-FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected vascular graft infections. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1359-1368.	6.4	28
74	Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9575-9575.	1.6	1
75	CT radiomics and PET radiomics: ready for clinical implementation?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 355-370.	0.7	58
76	Influence of inter-observer delineation variability on radiomics stability in different tumor sites. <i>Acta Oncologica</i> , 2018, 57, 1070-1074.	1.8	152
77	Value of 18F-FET PET in adult brainstem glioma. <i>Clinical Imaging</i> , 2018, 51, 68-75.	1.5	8
78	Pulmonary nodule detection in oncological patients – Value of respiratory-triggered, periodically rotated overlapping parallel T2-weighted imaging evaluated with PET/CT-MR. <i>European Journal of Radiology</i> , 2018, 98, 165-170.	2.6	13
79	[18F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level. <i>Molecular Imaging and Biology</i> , 2018, 20, 857-867.	2.6	33
80	Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 20-30.	6.4	72
81	Reduction of <sup>18</sup> F-FDG Dose in Clinical PET/MR Imaging by Using Silicon Photomultiplier Detectors. <i>Radiology</i> , 2018, 286, 249-259.	7.3	59
82	Impact of a Bayesian penalized likelihood reconstruction algorithm on image quality in novel digital PET/CT: clinical implications for the assessment of lung tumors. <i>EJNMMI Physics</i> , 2018, 5, 27.	2.7	51
83	Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease – Preliminary Experience From a Retrospective Analysis. <i>Clinical Nuclear Medicine</i> , 2018, 43, e385-e391.	1.3	11
84	Value of PET/MRI for assessing tumor resectability in NSCLC – intra-individual comparison with PET/CT. <i>British Journal of Radiology</i> , 2018, , 20180379.	2.2	8
85	Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks – Initial results. <i>Lung Cancer</i> , 2018, 126, 170-173.	2.0	90
86	Oral manifestation of Langerhans cell histiocytosis: a case report. <i>BMC Oral Health</i> , 2018, 18, 106.	2.3	24
87	Maximum Standardized Uptake Value (SUVmax) of Primary Tumor Predicts Occult Neck Metastasis in Oral Cancer. <i>Scientific Reports</i> , 2018, 8, 11817.	3.3	38
88	Feasibility of <sup>18</sup> F-FDG Dose Reductions in Breast Cancer PET/MRI. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1817-1822.	5.0	14
89	Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 685-690.	1.1	29
90	Imaging in primary hyperparathyroidism: focus on the evidence-based diagnostic performance of different methods. <i>Minerva Endocrinology</i> , 2018, 43, 133-143.	1.1	47

#	ARTICLE	IF	CITATIONS
91	Evaluation of multifunctional imaging parameters in gastro-oesophageal cancer using F-18-FDG-PET/CT with integrated perfusion CT. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, , .	0.7	1
92	Effect of Time-of-Flight Information on PET/MR Reconstruction Artifacts: Comparison of Free-breathing versus Breath-hold MR-based Attenuation Correction. Radiology, 2017, 282, 229-235.	7.3	16
93	The Effect of Susceptibility Artifacts Related to Metallic Implants on Adjacent-Lesion Assessment in Simultaneous TOF PET/MR. Journal of Nuclear Medicine, 2017, 58, 1167-1173.	5.0	8
94	PET+MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT+MR system. Clinical Imaging, 2017, 42, 232-239.	1.5	43
95	Comparison of Contrast-Enhanced CT and [18F]FDG PET/CT Analysis Using Kurtosis and Skewness in Patients with Primary Colorectal Cancer. Molecular Imaging and Biology, 2017, 19, 795-803.	2.6	32
96	Local resectability assessment of head and neck cancer: Positron emission tomography/MRI versus positron emission tomography/CT. Head and Neck, 2017, 39, 1550-1558.	2.0	35
97	PET/MR Outperforms PET/CT in Suspected Occult Tumors. Clinical Nuclear Medicine, 2017, 42, e88-e95.	1.3	37
98	Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1223-1233.	6.4	20
99	The Effect of Defective PET Detectors in Clinical Simultaneous [18F]FDG Time-of-Flight PET/MR Imaging. Molecular Imaging and Biology, 2017, 19, 626-635.	2.6	5
100	Assessment of prostate cancer with integrated CT-perfusion using a sector-wise approach. Turkish Journal of Urology, 2017, 43, 152-157.	1.3	1
101	Visualization of Parathyroid Hyperplasia Using 18F-Fluorocholine PET/MR in a Patient With Secondary Hyperparathyroidism. Clinical Nuclear Medicine, 2016, 41, e159-e161.	1.3	11
102	Clinical Evaluation of Zero-Echo-Time Attenuation Correction for Brain <sup>18</sup> F-FDG PET/MRI: Comparison with Atlas Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 1927-1932.	5.0	102
103	Evaluation of Atlas-Based Attenuation Correction for Integrated PET/MR in Human Brain: Application of a Head Atlas and Comparison to True CT-Based Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 215-220.	5.0	80
104	Multi-Atlas-Based Attenuation Correction for Brain <sup>18</sup> F-FDG PET Imaging Using a Time-of-Flight PET/MR Scanner: Comparison with Clinical Single-Atlas and CT-Based Attenuation Correction. Journal of Nuclear Medicine, 2016, 57, 1258-1264.	5.0	29
105	<sup>18</sup> F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response. Journal of Nuclear Medicine, 2016, 57, 849-854.	5.0	44
106	TNM Staging of Non-Small Cell Lung Cancer: Comparison of PET/MR and PET/CT. Journal of Nuclear Medicine, 2016, 57, 21-26.	5.0	65
107	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer, 2015, 15, 1002.	2.6	42
108	Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study. BMC Medical Imaging, 2015, 15, 60.	2.7	7

#	ARTICLE	IF	CITATIONS
109	PET/MR in Cancers of the Head and Neck. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 248-265.	4.6	69
110	Clinical evaluation of PET image quality as a function of acquisition time in a new TOF-PET/MR compared to TOF-PET/CT - initial results. <i>EJNMMI Physics</i> , 2015, 2, A76.	2.7	3
111	Dose Optimization in TOF-PET/MR Compared to TOF-PET/CT. <i>PLoS ONE</i> , 2015, 10, e0128842.	2.5	30
112	Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. <i>Swiss Medical Weekly</i> , 2015, 145, w14116.	1.6	11
113	Whole-Body Nonenhanced PET/MR versus PET/CT in the Staging and Restaging of Cancers: Preliminary Observations. <i>Radiology</i> , 2014, 273, 859-869.	7.3	78
114	Metal artifact reduction in patients with dental implants using multispectral three-dimensional data acquisition for hybrid PET/MRI. <i>EJNMMI Physics</i> , 2014, 1, 102.	2.7	36
115	PET/MRI and PET/CT in follow-up of head and neck cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1066-75.	6.4	68
116	Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT. <i>EJNMMI Research</i> , 2014, 4, 6.	2.5	7
117	Integrated CT-perfusion shows no meaningful correlation with PSA and presurgical Gleason score in patients with early prostate cancer. <i>Clinical Imaging</i> , 2014, 38, 850-857.	1.5	2
118	Clinical applications of SPECT/CT in imaging the extremities. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 50-58.	6.4	141
119	Cluster-based segmentation of dual-echo ultra-short echo time images for PET/MR bone localization. <i>EJNMMI Physics</i> , 2014, 1, 7.	2.7	18
120	Contrast-Enhanced PET/MR Imaging Versus Contrast-Enhanced PET/CT in Head and Neck Cancer: How Much MR Information Is Needed?. <i>Journal of Nuclear Medicine</i> , 2014, 55, 551-558.	5.0	123
121	Imaging Non-Specific Wrist Pain: Interobserver Agreement and Diagnostic Accuracy of SPECT/CT, MRI, CT, Bone Scan and Plain Radiographs. <i>PLoS ONE</i> , 2013, 8, e85359.	2.5	24